GREAT POINT PARTNERS LLC — 13F Holdings & Portfolio
CIK 1281446 · latest 13F-HR filed 2026-05-15
GREAT POINT PARTNERS LLC manages $435.1M in 13F-reported U.S. long-equity assets across 42 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are APGE (7.23%), VOR (7.18%), ZURA (5.77%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 18 new positions, exited 8, added to 15, and trimmed 4.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$435.1M
Long-equity book
42
Distinct positions
2026-03-31
Filed 2026-05-15
+18 / −8 / ↑15 / ↓4
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- NEKTAR THERAPEUTICS$13.9M +155.5%
- VOR BIOPHARMA INC$13.3M +74.2%
- CLIMB BIO INC$5.2M +133.2%
- ZURA BIO LTD$5.1M +25.5%
- ORUKA THERAPEUTICS INC$3.4M +61.8%
Top Trims
- IMMUNOVANT INC-$5.5M -28.9%
- CULLINAN THERAPEUTICS INC-$2.3M -35.0%
- CONTEXT THERAPEUTICS INC-$1.0M -14.8%
- AVALO THERAPEUTICS INC-$402.7K -17.8%
New Positions
- SOL-GEL TECHNOLOGIES LTD$21.7M
- ALUMIS INC$18.9M
- BRIGHT MINDS BIOSCIENCES INC$16.1M
- ANNEXON INC$13.8M
- ZENAS BIOPHARMA INC$10.2M
Exited Positions
- DISC MEDICINE INC$19.9M
- RAPT THERAPEUTICS INC$19.7M
- SOLENO THERAPEUTICS INC$18.5M
- DIANTHUS THERAPEUTICS INC$14.4M
- FULCRUM THERAPEUTICS INC$9.0M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $31.5M | 7.23% | 374,000 | SH |
| 2 | VOR BIOPHARMA INC | VOR | 929033207 | $31.2M | 7.18% | 1,750,000 | SH |
| 3 | ZURA BIO LTD | ZURA | G9TY5A101 | $25.1M | 5.77% | 4,215,930 | SH |
| 4 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $24.3M | 5.59% | 1,750,000 | SH |
| 5 | IMMUNITYBIO INC Put | IBRX | 45256X103 | $23.0M | 5.29% | 3,000,800 | SH |
| 6 | NEKTAR THERAPEUTICS | NKTR | 640268306 | $22.8M | 5.23% | 316,453 | SH |
| 7 | SOL-GEL TECHNOLOGIES LTD | SLGL | M8694L137 | $21.7M | 5.00% | 274,363 | SH |
| 8 | ALUMIS INC | ALMS | 022307102 | $18.9M | 4.33% | 856,061 | SH |
| 9 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 10919W405 | $16.1M | 3.69% | 220,000 | SH |
| 10 | ANNEXON INC | ANNX | 03589W102 | $13.8M | 3.18% | 2,500,000 | SH |
| 11 | KALVISTA PHARMACEUTICALS INC | KALV | 483497103 | $13.6M | 3.12% | 675,000 | SH |
| 12 | IMMUNOVANT INC | IMVT | 45258J102 | $13.6M | 3.11% | 545,625 | SH |
| 13 | JADE BIOSCIENCES INC | JBIO | 008064206 | $13.6M | 3.11% | 964,462 | SH |
| 14 | CONTINEUM THERAPEUTICS INC | CTNM | 21217B100 | $10.5M | 2.40% | 800,198 | SH |
| 15 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $10.2M | 2.35% | 524,066 | SH |
| 16 | NEUROGENE INC | NGNE | 64135M105 | $10.1M | 2.32% | 500,000 | SH |
| 17 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $9.3M | 2.14% | 500,000 | SH |
| 18 | CLIMB BIO INC | CLYM | 28658R106 | $9.1M | 2.10% | 1,334,130 | SH |
| 19 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $9.0M | 2.07% | 183,330 | SH |
| 20 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $8.7M | 2.00% | 1,200,000 | SH |
| 21 | VERA THERAPEUTICS INC | VERA | 92337R101 | $8.0M | 1.84% | 199,348 | SH |
| 22 | EVOMMUNE INC | EVMN | 30054Y107 | $7.5M | 1.72% | 325,000 | SH |
| 23 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $7.4M | 1.70% | 300,000 | SH |
| 24 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $7.1M | 1.64% | 1,350,000 | SH |
| 25 | SCYNEXIS INC | SCYX | 811292200 | $6.9M | 1.59% | 7,554,347 | SH |
| 26 | PALISADE BIO INC | PALI | 696389402 | $6.0M | 1.37% | 3,405,757 | SH |
| 27 | CONTEXT THERAPEUTICS INC | CNTX | 21077P108 | $5.9M | 1.35% | 2,238,496 | SH |
| 28 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $5.9M | 1.35% | 842,106 | SH |
| 29 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $5.4M | 1.24% | 1,020,489 | SH |
| 30 | UNICYCIVE THERAPEUTICS INC | UNCY | 90466Y202 | $5.2M | 1.20% | 796,558 | SH |
| 31 | TENAX THERAPEUTICS INC | TENX | 88032L605 | $5.2M | 1.20% | 327,307 | SH |
| 32 | PROMIS NEUROSCIENCES INC | PMN | 74346M505 | $4.7M | 1.08% | 371,402 | SH |
| 33 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $4.3M | 0.98% | 300,000 | SH |
| 34 | IMMIX BIOPHARMA INC | IMMX | 45258H106 | $3.2M | 0.73% | 350,000 | SH |
| 35 | REZOLUTE INC | RZLT | 76200L309 | $2.9M | 0.67% | 951,809 | SH |
| 36 | PHARVARIS N V | PHVS | N69605108 | $2.3M | 0.54% | 82,800 | SH |
| 37 | HUMACYTE INC | HUMA | 44486Q103 | $2.3M | 0.52% | 3,750,000 | SH |
| 38 | GALECTIN THERAPEUTICS INC Call | GALT | 363225202 | $2.2M | 0.51% | 800,000 | SH |
| 39 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $1.9M | 0.43% | 124,666 | SH |
| 40 | ALKERMES PLC | ALKS | G01767105 | $1.8M | 0.41% | 50,000 | SH |
| 41 | ANAVEX LIFE SCIENCES CORP Call | AVXL | 032797300 | $1.6M | 0.37% | 521,300 | SH |
| 42 | OPUS GENETICS INC | IRD | 67577R102 | $1.5M | 0.34% | 324,340 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $435.1M | 42 | 0001172661-26-002272 |
| 2025-12-31 | 2026-02-17 | $308.4M | 29 | 0001172661-26-001093 |
| 2025-09-30 | 2025-11-14 | $242.5M | 30 | 0001814554-25-000164 |